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Biomarkers to Assess Right Heart Pressures
in Recipients of a Heart Transplant:
A Proof-of-Concept Study
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Johan Vanhaecke, MD, PhD,3 Stefan Janssens, MD, PhD,3 Johan Van Cleemput, MD, PhD,3
Harald Mischak, PhD,4,5 and Jan A. Staessen, MD, PhD1,6
Background.This proof-of-concept study investigated the feasibility of using biomarkers tomonitor right heart pressures (RHP)
in heart transplanted (HTx) patients.Methods. In 298 patients, we measured 7.6 years post-HTx mean pressures in the right
atrium (mRAP) and pulmonary artery (mPAP) and capillaries (mPCWP) along with plasma high-sensitivity troponin T (hsTnT), a
marker of cardiomyocyte injury, and the multidimensional urinary classifiers HF1 and HF2, mainly consisting of dysregulated collagen
fragments. Results. In multivariable models, mRAP and mPAP increased with hsTnT (per 1-SD, +0.91 and +1.26 mm Hg;
P < 0.0001) and with HF2 (+0.42 and +0.62 mm Hg; P ≤ 0.035), but not with HF1. mPCWP increased with hsTnT (+1.16 mm Hg;
P < 0.0001), but not with HF1 or HF2. The adjusted odds ratios for having elevated RHP (mRAP, mPAP or mPCWP ≥10, ≥24,
≥17 mm Hg, respectively) were 1.99 for hsTnTand 1.56 for HF2 (P ≤ 0.005). In detecting elevated RHPs, areas under the curve were
similar for hsTnTand HF2 (0.63 vs 0.65; P = 0.66). Adding hsTnTcontinuous or per threshold or HF2 continuous to a basic model
including all covariables did not increase diagnostic accuracy (P ≥ 0.11), whereas adding HF2 per optimized threshold increased
both the integrated discrimination (+1.92%; P = 0.023) and net reclassification (+30.3%; P = 0.010) improvement.Conclusions.
Correlating RHPs with noninvasive biomarkers in HTx patients is feasible. However, further refinement and validation of such
biomarkers is required before their clinical application can be considered.
(Transplantation Direct 2018;4: e346; doi: 10.1097/TXD.0000000000000783. Published online 23 April, 2018.)
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Heart transplantation (HTx) is the treatment of choicefor a highly selected group of terminally ill heart failure
patients with severe symptoms not responding to optimal
medical therapywith the goal to prolong survival and improve
quality of life.1 Right heart catheterization, sometimes performed
simultaneouslywithobtaining surveillance endomyocardial biop-
sies (EMB), is a standard way tomonitor cardiac hemodynamics
of patients after HTx.
Aposition paper of theAmericanHeartAssociation supports
research into proteomics as applied to cardiovascular health
and diseasewith the goal to discover newand effective strategies
for the prevention, diagnosis and treatment of cardiovascular
disease.2 This proof-of-concept study3 builds on previously iden-
tified multidimensional urinary proteomic classifiers.4-6 HF1
consists of 85 peptide fragments and was originally devel-
oped in a case-control study nested within the Flemish Study
on Environment, Genes andHealth Outcomes5 with the goal
to identify potentially discriminating urinary biomarkers for
asymptomatic diastolic left ventricular (LV) dysfunction. The
HF2 classifier was designed by including also patients with
advanced heart failure and consists of 671 peptide fragments.4,6
The current hypothesis-driven study is a first attempt to assess
the feasibility of correlating HTx graft performance with uri-
nary proteomic biomarkers, because invasive right heart cath-
eterization causes discomfort and sometime life-threatening
complications. To address this objective, we correlated right
heart pressures (RHPs) with the previously established
HF14,5 and HF24,6 urinary biomarkers in 298 post-HTx pa-
tients.We also studied plasma high-sensitivity cardiac troponin
T (hsTnT) as a circulating biomarker of cardiomyocyte injury in
HTx patients.7 In the general population, hsTnT is associated
with LV and left atrial remodeling and dysfunction8 and even
outside the context of myocardial ischemia predicts the inci-
dence of heart failure and all-cause mortality.9,10
MATERIALS AND METHODS
Study Participants
Urinary Proteomics in Predicting Heart Transplantation
Outcomes (uPROPHET; registration number at www.
clinicaltrials.gov, NCT03152422) complies with theHelsinki
declaration for research in humans.11 The Ethics Committee
of the University Hospitals Leuven (approval numbers
B322201421186 [S56384] and B322201421045 [S56472])
and the officers of the European Research Council Executive
Agency approved uPROPHET. Heart transplant recipients
provided written informed consents. Recruitment of patients
took place at the University Hospital Gasthuisberg in Leuven
(2014-2015) in collaboration with the HTx team. All surviving
HTx recipients in regular follow-up at the University Hospitals
Leuven were invited to provide a 5-mLmidmorning urine sam-
ple. Of 352 study participants, 298 had undergone invasive
right heart catheterization within 6 months of the urine sam-
pling and were included in the present analysis.
Collection of Clinical Data
A detailed description of the construction and contents of
uPROPHET database is available elsewhere.3 The policy im-
plemented at the University Hospital Leuven is that EMBs
are generally performed weekly for the first month, then ev-
ery 2 weeks during the second month, at variable intervals
during the third and fourth month, and monthly through
months 8 to 12. After 1 year, biopsies are done every 4 to
6 months. After a treated episode of rejection, EMB is gener-
ally repeated within 14 days to ensure that immunosuppres-
sion is adequate. Right heart hemodynamic measurements
included mean pressures in the right atrium (mRAP), mean
pulmonary arterial pressure (mPAP), mean pulmonary capillary
wedge pressure (mPCWP) and right ventricular systolic (sRVP)
and diastolic (dRVP) pressures. The RHPs were recorded aver-
aged over the respiratory cycle. In categorical analyses, we ap-
plied the 75th percentiles of mRAP (≥10 mm Hg), mPAP
(≥24 mm Hg) and mPCWP (≥17 mm Hg) to define elevated
RHP. All potentially relevant clinical information, including
EMB histopathology, tests for antibody-mediated rejection per-
formed if clinically indicated, and use of immunosuppressive
drugs was retrieved from the computerized information system
of the University Hospitals Leuven. Ejection fraction was de-
termined by echocardiography. Hypertension was an office
blood pressure of at least 140 mm Hg systolic or 90 mm Hg
diastolic or use of antihypertensive drugs. Body mass index
was weight in kilograms divided by height in meters squared.
Urinary Proteomics
Methods for urine sample preparation, proteome analysis
by capillary electrophoresis coupled to mass spectrometry,
data processing, and sequencing have been published before.12,13
Peptides were combined into a single summary variables,
using the MosaCluster software, version 1.7.0.14 HF1 was
originally derived in a case-control study including partici-
pants with mild and moderate LV diastolic dysfunction. It
consists of 85 peptides mainly collagen fragments.4,5 HF1 is
a robust urinary biomarker validated before in case-control
studies5 and in the general population.4 To generate the HF2
classifier, all urinary proteomic data sets from cases available
in the Mosaiques database15 were combined and compared
with data from sex- and age-matched controls. Cases were
98 patients with LV diastolic dysfunction recruited from the
population (n = 35)5 or admitted to the hospital because of
overt heart failure (n = 63).4,6 The underlying cause of heart
failure was ischemic (50.8%), dilated (28.6%), or hypertro-
phic (1.6%) cardiomyopathy, valvular heart disease (1.6%)
or unspecified (17.4%). Comparing cases with controls identi-
fied 710 potential biomarkers, based on a P value less than
0.05 with adjustment for multiple testing applied. Using a
take-one-out procedure16 to remove potential biomarkers that
are of no apparent value, the number of peptides was reduced
to 671. Both HF1 and HF2 are normally distributed, higher
values being associated with worse outcomes.4-6
High-Sensitivity Cardiac Troponin T
Blood sampling for hsTnT took place on the same date as
urine sampling. High-sensitivity cardiac troponin T concen-
trations were measured in plasma, using the hsTnT one-step
electrochemiluminescence immunoassay on an Elecsys 2010
analyzer (Roche Diagnostics, Meylan, France). The measur-
ing range extended from 0.003 to 10 μg/L. The diagnostic
threshold for myocardial damage is 0.014 μg/L or greater
(99th percentile).17
Statistical Analysis
For database management and statistical analysis, we used
the SAS system, version 9.4 (SAS Institute Inc., Cary, NC).
Meanswere compared using the large-sample z test or analysis
of variance and proportions by Fisher exact test. Based on the
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Wilk-Shapiro test, we logarithmically transformed the distri-
bution of hsTnT to approximate normality. Our statistical
methods also includemultivariable-adjusted linear and logistic
regression with the right heart hemodynamic indexes as de-
pendent variables on a continuous or binary scale. We ad-
justed the analyses for covariables of physiological relevance,
including age, years after HTx, body mass index, mean arte-
rial pressure (diastolic plus one third of the difference between
systolic and diastolic blood pressure on office measurement),
heart rate (during right heart catheterization), and serum cre-
atinine. In addition to these covariables, fully adjusted models
also accounted for use of immunosuppressive agents by drug
class, including methylprednisolone and intake of antihyper-
tensive drugs. We constructed the RHP score (RHPS [0, 1],
which equaled 1, if any mean RHP (mRAP, mPAP, or
mPCWP) was equal to or higher than the 75th percentile of
its distribution and 0 otherwise. In categorical analyses, we
used the published threshold of 0.014 μg/L or greater for
hsTnT.17 For HF1 and HF2, we determined optimal discrimi-
nation limits to categorize patients according to their RHPS by
maximizing Youden Index (the maximum of sensitivity plus
specificity minus 1). We evaluated the capability to discrimi-
nate between patients with or without elevated RHPs by con-
structing receiver operating characteristic (ROC) curves and
by calculating the area under the ROC curve (AUC). The
95% confidence interval (CI) of the AUC was calculated by
theDeLongmethod. Finally, we assessed the incremental value
of the urinary biomarkers in discriminating between normal
and abnormal right heart hemodynamics, while adjusting for
covariables, using the integrated discrimination improvement
(IDI) and the net reclassification improvement (NRI).18
RESULTS
Patients Characteristics
Among the 298 study participants, the underlying cause of
treatment-resistant end-stage heart failure, which constituted
the indication for HTx, was ischemic cardiomyopathy in 121
(40.6%) patients and dilated cardiomyopathy (DCM) in 116
(38.9%). Among the remaining 61 patients, the etiology of
heart failure included hypertrophic cardiomyopathy (n = 19),
restrictive (n = 5), valvular (n = 10) or congenital (n = 18) heart
disease, arrhythmogenic right ventricular dysplasia (n = 3),
constrictive pericarditis (n = 1), cardiac sarcoidosis (n = 1),
myocarditis (n = 3), and irreversible myocardial damage
caused by a massive hemorrhage (n = 1). The 298 patients
underwent surgery from August 1988 until April 2015 and
included 68 (22.8%) women. Mean (±SD) age of the donors
was 36.2 ± 12.9 years.
Tables 1, 2, and 3 lists the characteristics of the patients by
quartiles of the distributions of mRAP, mPAP, and mPCWP,
respectively. Patients with RHP above the 75th percentile,
had a higher frequency of diabetes mellitus or history of ische-
mic cardiomyopathy, were older, had higher body mass index
and were more likely to be past smokers. The number of pa-
tients that underwent EMBwithin 6months of urine sampling
totaled 73. Of the biopsy specimens, 51 (69.9%) had no rejec-
tion (grade 0), 19 (26.0%), and 3 (4.1%) had grade 1A or 1B
rejection. There were no grade 2 or higher rejections. Evidence
of positive C4d staining occurred in 18 (6%) patients.
Figure 1 shows the distributions of hsTnT, HF1 and HF2
dichotomized by RHPS. The median values of mRAP,
mPAP, and mPCWP among all 298 patients were 9 mm Hg
TABLE 1.
Characteristics of patients categorized by quartiles of mean right atrial pressure
Characteristic mRAP quartiles P
Pressure limits, mm Hg <7 7-9 9-10 >10
Number (%) with characteristics 74 75 74 75
Women 21 (28.4) 20 (26.7) 16 (21.6) 11 (14.7) 0.035
Past smoker 40 (54.1) 42 (56.0) 58 (78.4)b 57 (76.0) 0.0004
Hypertension 60 (81.1) 68 (90.7) 66 (89.2) 69 (92.0) 0.064
Diabetes mellitus 11 (14.9) 13 (17.3) 25 (33.8)a 28 (37.3) 0.0003
Ischemic cardiomyopathy 21 (28.4) 28 (37.3) 40 (54.1)a 32 (42.7) 0.020
DCM 31 (41.9) 30 (40.0) 27 (36.5) 28 (37.3) 0.50
Other etiology 22 (29.7) 17 (22.7) 7 (9.5)a 15 (20.0) 0.045
Mean (±SD) of characteristics
Time since transplantation, y 4.1 (1.8-10.9) 6.3 (1.8-13.2) 11.4 (4.3-16.6)a 9.5 (5.4-14.3) 0.0008
Age, y 51.4 ± 16.3 55.9 ± 14.8a 59.9 ± 12.0 62.2 ± 11.8 <0.0001
Body mass index, kg/m2 22.9 ± 3.4 24.2 ± 3.5a 26.0 ± 3.9b 27.6 ± 4.4b <0.0001
Systolic pressure, mm Hg 141.4 ± 20.3 141.9 ± 21.6 143.9 ± 21.7 143.1 ± 23.5 0.49
Diastolic pressure, mm Hg 85.9 ± 10.7 85.4 ± 11.9 84.9 ± 10.6 84.3 ± 12.8 0.37
Ejection fraction, % 58.8 ± 2.7 59.4 ± 2.6 59.5 ± 2.5 59.5 ± 2.7 0.10
Creatinine, mg/dL 1.30 ± 0.43 1.48 ± 0.48a 1.52 ± 0.49 1.51 ± 0.52 0.006
Total cholesterol, mg/dL 155.7 ± 34.9 161.5 ± 40.6 158.8 ± 36.7 150.8 ± 29.2 0.37
HDL-cholesterol, mg/dL 59.7 ± 17.3 59.7 ± 17.4 56.4 ± 18.7 53.8 ± 15.0 0.017
Troponin T, μg/L (E−2) 1.4 (0.5-1.7) 2.0 (0.7-2.0)a 2.0 (0.8-2.4) 2.5 (1.0-2.7) <0.0001
HF1 −0.34 ± 1.02 0.05 ± 0.98a 0.10 ± 0.91 0.19 ± 1.02 0.001
HF2 −0.43 ± 0.91 −0.03 ± 0.96b 0.10 ± 0.87 0.36 ± 1.09 <0.0001
Significance of the difference with the adjacent lower quartile: a P ≤ 0.05; b P ≤ 0.01.
The central tendency of the data is represented by the median (IQR) for time since transplantation and by the geometric mean (IQR) for troponin T. Hypertension was a blood pressure of≥140 mm Hg systolic or
≥90 mm Hg diastolic or use of antihypertensive drugs.
HDL, high-density lipoprotein.
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(interquartile range [IQR], 7-10 mm Hg), 21 mm Hg (IQR,
18-24 mmHg) and 14 mmHg (IQR, 11-17 mm Hg) respec-
tively. Patients with higher versus lower RHPs had higher
values of hsTnT (0.017 vs 0.011 μg/L; P < 0.0001), HF1
(−0.41 vs –0.82; P = 0.0005), and HF2 (0.18 vs –0.19;
P < 0.0001). Figure 2 shows mRAP, mPAP, and mPCWP as
a function of time since transplantation. Mean pressures in
the right atrium (P = 0.004) increased with higher time inter-
val since HTx, whereas mPAP (P = 0.16) and mPCWP
(P = 0.45) did not.
Use of Medications
Of 298 patients, 65 (21.8%) were taking cyclosporine,
225 (75.5%) tacrolimus, 232 (77.9%) mycophenolate mofetil,
17 (5.7%) everolimus, 20 (6.7%) azathioprine, and
105 (35.2%) methylprednisolone. Fifteen (5.0%) were tak-
ing a single drug, 200 (67.1%) 2 drugs, and 83 (27.9%) 3
drugs. The most common combination was tacrolimus plus
mycophenolate mofetil (177 patients; 59.4%). The number
of patients taking 1 or more antihypertensive drugs was
231 (77.5%), of whom 57 (24.7%) were on thiazide or loop di-
uretics, 113 (48.9%)onβ-blockers, 140 (60.6%)onangiotensin-
converting enzyme inhibitors or angiotensin I receptor blockers,
90 (39.0%) on calcium-channel blockers, and 19 (8.2%) on al-
dosterone antagonists. The number of patients on antidiabetic
treatment totaled 81, of whom 50 (61.7%)were on oral therapy
and 31 (38.3%) on insulin. The time interval between right heart
catheterization and urine sampling was 91 days (IQR,
84-105 days). Over this time, interval changes in medication
use were minimal.
Per 1 unit increment in the number of immunosup-
pressive drugs, hsTnT increased by 21.4% (95% CI,
14.0-28.9; P < 0.0001), HF1 by 0.243 (95% CI, 0.022-0.464;
P = 0.033), and HF2 by 0.159 (95% CI, 0.010-0.308;
P = 0.038). Per 1 unit increase in the number of antihyperten-
sive drugs taken, these estimates were 4.0% (95% CI,
0.4-7.5; P = 0.032) for hsTnT, 0.339 (95% CI, 0.243-0.435;
P < 0.0001) for HF1, and 0.272 (95% CI, 0.209-0.335;
P < 0.0001) for HF2.
Associations of RHPs with Biomarkers
The correlation coefficients between hsTnT and HF1,
hsTnT and HF2, and HF1 and HF2 were 0.38, 0.36, and
0.63, respectively (P < 0.0001).
Continuous Outcomes
In unadjusted analyses, all RHPs increased with hsTnT,
HF1, and HF2 (Table 4). In adjusted models, mRAP, mPAP,
sRVP, and dRVP, all increased with hsTnT and HF2.
Expressed per 1-SD increment in the biomarker, the increases in
RHPs ranged from 0.67 mm Hg (P = 0.0001) to 1.67 mm Hg
(P < 0.0001) for hsTnT and from 0.34 mm Hg (P = 0.051)
to 0.92 mm Hg (P = 0.018) for HF2 (Table 4). With
additional adjustments for use of immunosuppressive (by
class) and antihypertensive drugs, these estimates ranged
from 0.91 mm Hg (P < 0.0001) to 1.64 mm Hg (P = 0.0001)
for hsTnT and from 0.42 mm Hg (P = 0.020) to 0.89 mm Hg
(P = 0.027) for HF2 (Table 4 and Figure 3). In adjusted and
fully adjusted models mPCWP increased with hsTnT
(≥0.93 mm Hg; P ≤ 0.0005), whereas the increase in
mPCWP associated with HF2 did not reach significance
(≥0.24 mm Hg; P ≥ 0.27). With partial and full adjustments
applied, none of the RHPs remained significantly associated
with HF1 (P ≥ 0.12). Excluding 24 patients on loop
TABLE 2.
Characteristics of patients categorized by quartiles of mean pulmonary arterial pressure
Characteristics mPAP quartiles P
Pressure limits, mm Hg <18 18-21 21-24 >24
Number (%) with characteristics 74 74 75 75
Women 14 (18.9) 21 (28.4) 16 (21.3) 17 (22.7) 0.85
Past smoker 43 (58.1) 45 (60.8) 51 (68.0) 58 (77.3) 0.009
Hypertension 62 (83.8) 62 (83.8) 71 (94.7)a 68 (90.7) 0.062
Diabetes mellitus 9 (12.2) 15 (20.3) 22 (29.3) 31 (41.3) <0.0001
Ischemic cardiomyopathy 23 (31.1) 25 (33.8) 32 (42.7) 41 (54.7) 0.002
DCM 33 (44.6) 30 (40.5) 31 (41.3) 22 (29.3) 0.076
Other etiology 18 (24.3) 19 (25.7) 12 (16.0) 12 (16.0) 0.099
Mean (±SD) of characteristics
Time since transplantation, y 5.4 (2.3‐12.8) 7.6 (3.2‐13.9) 10.6 (2.7-14.6) 8.3 (4.3-14.3) 0.068
Age, y 50.5 ± 16.0 55.4 ± 14.4a 60.1 ± 12.7a 63.5 ± 10.7 <0.0001
Body mass index, kg/m2 23.3 ± 3.4 24.3 ± 3.3 25.4 ± 4.0 27.7 ± 4.8c <0.0001
Systolic pressure, mm Hg 138.5 ± 18.5 141.5 ± 22.4 146.4 ± 21.1 143.6 ± 24.1 0.081
Diastolic pressure, mm Hg 86.1 ± 11.3 84.8 ± 10.5 85.8 ± 11.9 83.8 ± 12.2 0.29
Ejection fraction, % 59.1 ± 2.6 59.5 ± 1.9 59.0 ± 2.9 59.5 ± 2.8 0.55
Creatinine, mg/dL 1.26 ± 0.38 1.44 ± 0.50 1.57 ± 0.53 1.53 ± 0.51 0.0002
Total cholesterol, mg/dL 157.5 ± 33.7 158.6 ± 36.1 156.1 ± 37.9 154.6 ± 35.3 0.58
HDL-cholesterol, mg/dL 58.2 ± 16.7 58.7 ± 17.9 56.4 ± 15.9 56.4 ± 18.5 0.50
Troponin T, μg/L (E−2) 1.4 (0.6-1.7) 1.8 (0.6-1.9) 2.1 (0.9-2.4) 2.6 (1.0-3.0) <0.0001
HF1 −0.24 ± 1.07 −0.20 ± 0.94 0.15 ± 0.97a 0.29 ± 0.93 <0.0001
HF2 −0.44 ± 0.87 −0.15 ± 0.95 0.23 ± 0.86b 0.35 ± 1.12 <0.0001
Significance of the difference with the adjacent lower quartile: a P ≤ 0.05; b P ≤ 0.01; c P ≤ 0.001.
The central tendency of the data is represented by the median (IQR) for time since transplantation and by the geometric mean (IQR) for troponin T. Hypertension was a blood pressure of≥140 mm Hg systolic or
≥90 mm Hg diastolic or use of antihypertensive drugs.
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diuretics or 57 patients on any diuretic produced results
not different from those reported in Table 4. In fully
adjusted models, the interaction terms of diuretic use
versus nonuse in association with the urinary biomarkers
were nonsignificant (P ≥ 0.089).
Analyses limited to 119 patients, who had their urine sample
collected within 3 months of the right heart catheterization
provided estimates of the fully adjusted association sizes
comparable with those reported in Table 4. The estimates
per 1-SD increment in the biomarkers were 0.88 mm Hg
(95% CI, 0.28-1.49 mm Hg; P = 0.004), 1.00 mm Hg (95%
CI, 0.09-1.91 mm Hg; P = 0.032) and 0.87 mm Hg (95%
CI, 0.03-1.71 mm Hg; P = 0.043) for mRAP, mPAP, and
mPCWP in relation to hsTnT; 0.49 mm Hg (95% CI, -0.05
to 1.04 mm Hg; P = 0.077), 0.67 mm Hg (CI, -0.15 to
1.49 mm Hg; P = 0.11) and 0.13 mm Hg (95% CI, -0.63 to
0.89 mm Hg; P = 0.73) for mRAP, mPAP, and mPCWP in re-
lation to HF1; and 0.75 mmHg (95% CI, 0.20-1.29 mmHg;
P = 0.008), 1.06 mm Hg (CI, 0.24-1.87 mm Hg; P = 0.012),
and 0.70 mm Hg (95% CI, -0.06 to 1.46 mm Hg; P = 0.072)
formRAP,mPAP, andmPCWP in relation toHF2. The interac-
tion terms of the urinary biomarkers with time interval relative
to right heart catheterization (≤3 vs >3 months) were all non-
significant (P ≥ 0.073).
Categorical Outcomes
In categorical analyses, we set the threshold for elevated
RHPs at the 75th percentile (Table 5). The odds of having
FIGURE 1. Frequency distributions of hsTnT, HF1 and HF2 by RHPS (0, 1). This score is 1 if any mean RHP is equal to or higher than the 75th
percentile (mean right atrial pressure, ≥10 mm Hg; mean pulmonary arterial pressure, ≥24 mm Hg; or pulmonary capillary wedge pressure,
≥17 mmHg) and 0 otherwise. Mean values (given at the top of the distribution plots) were in patients with elevated RHPS or not (P ≤ 0.0005).
TABLE 3.
Characteristics of patients categorized by quartiles of mean pulmonary capillary wedge pressure
Characteristics mPCWP quartiles P
Pressure limits, mm Hg <11 11-14 14-17 >17
Number (%) with characteristics 74 75 74 75
Women 21 (28.4) 19 (25.3) 12 (16.2) 16 (21.3) 0.17
Past smoker 44 (59.5) 44 (58.7) 51 (68.9) 58 (77.3) 0.010
Hypertension 62 (83.8) 66 (88.0) 65 (87.8) 70 (93.3) 0.090
Diabetes mellitus 17 (23.0) 15 (20.0) 16 (21.6) 29 (38.7)a 0.032
Ischemic cardiomyopathy 27 (36.5) 30 (40.0) 23 (31.1) 41 (54.7)b 0.072
DCM 30 (40.5) 28 (37.3) 35 (47.3) 23 (30.7)a 0.43
Other etiology 17 (23.0) 17 (22.7) 16 (21.6) 11 (14.7) 0.21
Mean (±SD) of characteristics
Time since transplantation, y 7.4 (2.3-15.4) 7.4 (2.5-13.2) 7.5 (3.2-14.5) 8.3 (4.3-14.3) 0.36
Age, y 51.4 ± 16.3 55.9 ± 14.8 59.9 ± 12.0 62.2 ± 11.8 0.001
Body mass index, kg/m2 22.9 ± 3.4 24.2 ± 3.5 26.0 ± 3.9 27.6 ± 4.4c <0.0001
Systolic pressure, mm Hg 141.4 ± 20.3 141.9 ± 21.6 143.9 ± 21.7 143.1 ± 23.5 0.34
Diastolic pressure, mm Hg 85.9 ± 10.7 85.4 ± 11.9 84.9 ± 10.6 84.3 ± 12.8 0.88
Ejection fraction, % 58.8 ± 2.7 59.4 ± 2.6 59.5 ± 2.5 59.5 ± 2.7 0.10
Creatinine, mg/dL 1.30 ± 0.43 1.48 ± 0.48 1.52 ± 0.49 1.51 ± 0.52 0.058
Total cholesterol, mg/dL 155.7 ± 34.9 161.5 ± 40.6 158.8 ± 36.7 150.8 ± 29.2 0.34
HDL-cholesterol, mg/dL 59.7 ± 17.3 59.7 ± 17.4 56.4 ± 18.7 53.8 ± 15.0 0.16
Troponin T, μg/L (E−2) 1.8 (0.7-2.0) 1.7 (0.6-2.4) 1.6 (0.7-1.7) 2.8 (1.1-3.1) 0.0006
HF1 −0.34 ± 1.02 0.05 ± 0.98 0.10 ± 0.91 0.19 ± 1.02 0.11
HF2 −0.43 ± 0.91 −0.03 ± 0.96 0.10 ± 0.87 0.36 ± 1.09a 0.0004
Significance of the difference with the adjacent lower quartile: a P ≤ 0.05; b P ≤ 0.01; c P ≤ 0.001.
The central tendency of the data is represented by the median (IQR) for time since transplantation and by the geometric mean (IQR) for troponin T. Hypertension was a blood pressure of≥140 mm Hg systolic or
≥90 mm Hg diastolic or use of antihypertensive drugs.
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an elevated mRAP, mPAP, or mPCWP increased with hsTnT.
In adjusted models, the odds ratios associated with a 1-SD
increment in hsTnT were 1.86 for mRAP, 1.88 for mPAP,
and 2.24 for mPCWP (P ≤ 0.0004) and in fully adjusted
models 2.36, 1.98, and 2.58 (P ≤ 0.0005), respectively. The
odds ratios for a 1-SD increment in HF2 were 1.53
(P = 0.007) for mRAP, 1.35 (P = 0.060) for mPAP, and 1.29
(P = 0.12) for mPCWP in adjusted models and in fully
adjusted models 1.61 (P = 0.005), 1.42 (P = 0.041), and
1.34 (P = 0.094), respectively. The odds of exceeding any
threshold in adjusted and fully adjusted models were 1.89
and 1.99 for hsTnT (P ≤ 0.0002) and 1.50 and 1.56
(P ≤ 0.007) for HF2. With partial and full adjustments
applied, none of the odds ratios remained significant for
HF1 (P ≥ 0.063). In a sensitivity analysis, we set the
threshold for mPCWP to the guideline-endorsed value of
15 mm Hg (71st percentile in our data) instead of 17 mm Hg
(75th percentile). In fully adjusted models, the odds of
having an elevated mPCWP then were 1.43 (95% CI, 1.03-
1.98; P = 0.033), 0.99 (95% CI, 0.74-1.32; P = 0.92), and
1.14 (95% CI, 0.85-1.52; P = 0.39) in relation to hsTnT,
HF1, and HF2. Based on the results given in Tables 4 and
5, hsTnT and HF2 were carried through in further analyses.
Diagnostic Accuracy
Unadjusted Analyses
To differentiate normal from elevated RHP, we used
0.014 μg/L or greater17 as diagnostic threshold for hsTnT, a
value approximately equal to the median of its distribution
in our data. The threshold for HF2 obtained by optimizing
the Youden index was 0.15 or higher. In all patients, these
thresholds yielded a sensitivity of 56.8% for hsTnT and
52.5% for HF2with a specificity of 59.8% and 71.1%, respec-
tively (Table 6). These estimates were similar in patients with
ischemic and DCM (Table 6). Replacing the hsTnT threshold
of 0.014 μg/L or greater by the optimized threshold of
0.009 μg/L or greater did not materially change the findings
reported in Table 6.
In all patients, the AUCs were similar for hsTnT and HF2
(0.63 [95% CI, 0.57-0.69] vs 0.65 [95% CI, 0.58-0.71],
P = 0.66; Figure 4). Among patients with ischemic
TABLE 4.
Association of RHPs with biomarkers
Measurements
hsTnT HF1 HF2
Estimate (CI) P Estimate (CI) P Estimate (% CI) P
mRAP, mm Hg
Unadjusted 0.68 (0.35 to 1.01) <0.0001 0.48 (0.14 to 0.81) 0.005 0.75 (0.42 to 1.08) <0.0001
Adjusted 0.67 (0.33 to 1.00) 0.0001 0.12 (−0.21 to 0.45) 0.48 0.34 (−0.00 to 0.68) 0.051
Fully adjusted 0.91 (0.54 to 1.28) <0.0001 0.17 (−0.18 to 0.53) 0.34 0.42 (0.07 to 0.78) 0.020
mPAP, mm Hg
Unadjusted 1.39 (0.88 to 1.90) <0.0001 0.98 (0.45 to 1.50) 0.0003 1.27 (0.75 to 1.79) <0.0001
Adjusted 1.21 (0.66 to 1.76) <0.0001 0.38 (−0.16 to 0.93) 0.17 0.62 (0.06 to 1.17) 0.030
Fully adjusted 1.26 (0.65 to 1.87) <0.0001 0.33 (−0.25 to 0.90) 0.26 0.62 (0.04 to 1.20) 0.035
sRVP, mm Hg
Unadjusted 1.81 (1.13 to 2.49) <0.0001 1.20 (0.51 to 1.90) 0.0008 1.58 (0.90 to 2.27) <0.0001
Adjusted 1.67 (0.91 to 2.42) <0.0001 0.59 (−0.16 to 1.33) 0.12 0.92 (0.16 to 1.68) 0.018
Fully adjusted 1.64 (0.81 to 2.48) 0.0001 0.52 (−0.27 to 1.31) 0.20 0.89 (0.10 to 1.68) 0.027
dRVP, mm Hg
Unadjusted 0.70 (0.32 to 1.07) 0.0003 0.48 (0.10 to 0.86) 0.014 0.69 (0.32 to 1.07) 0.0003
Adjusted 0.83 (0.44 to 1.22) <0.0001 0.26 (−0.13 to 0.64) 0.20 0.41 (0.02 to 0.81) 0.042
Fully adjusted 0.99 (0.56 to 1.42) <0.0001 0.23 (−0.18 to 0.64) 0.27 0.47 (0.06 to 0.88) 0.026
mPCWP, mm Hg
Unadjusted 0.91 (0.44 to 1.38) 0.0002 0.19 (−0.29 to 0.67) 0.44 0.64 (0.16 to 1.12) 0.009
Adjusted 0.93 (0.41 to 1.45) 0.0005 −0.20 (−0.72 to 0.31) 0.43 0.24 (−0.28 to 0.76) 0.37
Fully adjusted 1.16 (0.59 to 1.73) <0.0001 −0.21 (−0.75 to 0.33) 0.44 0.31 (−0.24 to 0.85) 0.27
Estimates express the difference in the RHPs (95% CI) associated with a 1-SD increment of the biomarkers. Adjusted models account for years since transplantation, age, body mass index, mean arterial pressure
(diastolic pressure plus one third of pulse pressure on office measurement), heart rate during the right heart catheterization and serum creatinine. Fully adjusted models additionally account for use of immuno-
suppressive (by class) and antihypertensive drugs.
FIGURE 2. mRAP, mPAP, and mPCWP plotted as a function of the
time interval since HTx. Plotted values are averages for each time
point. n indicates the number of patients contributing to the estimates.
Vertical bar denote the SD. P values are for linear trend.
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cardiomyopathy, the AUC was slightly but not significantly
smaller for hsTnT compared with HF2 (0.56 [95% CI,
0.46-0.67] vs 0.67 [95% CI, 0.58-0.77], P = 0.079;
Figure 4). In patients with DCM, estimates were similar for
hsTnT and HF2 (0.62 [CI, 0.52 to 0.73] vs 0.63 [CI, 0.52
to 0.73], P = 0.95; Figure 4).
Adjusted Analyses
Adding hsTnTcontinuous or per threshold or HF2 contin-
uous to a basic model including all covariables (Table 7) did
not increase IDI (P ≥ 0.11) or NRI (P ≥ 0.16). Adding HF2
per threshold increased both IDI (+1.92%; P = 0.023) and
NRI (+30.3%; P = 0.010).
DISCUSSION
This proof-of-concept study demonstrated that correlating
RHPs with biomarkers in HTx recipients is feasible. Mean
pressures in the right atrium and mPAP increased with
plasma hsTnT, a marker of cardiomyocyte injury, and with
HF2, a multidimensional urinary proteomic classifier mainly
consisting of dysregulated collagen fragments. In unadjusted
analyses, the AUCwas similar for hsTnTandHF2.However,
adding hsTnT to a basic model including all covariables did
not increase diagnostic accuracy, whereas HF2 did. By design,
HF1 is associated with early asymptomatic LV dysfunction,4,5
whereas HF2 reflects more advanced LV dysfunction.4 This
probably explains the null findings for HF1 in the current
study. Although our study suggests that assessing RHPs by
noninvasive biomarkers is feasible, it also highlights that fur-
ther refinement and validation of such biomarkers is required
before their clinical application inHTxpatients is possible. Im-
proving the diagnostic accuracy of hsTnT is difficult, because
it is a single protein released from injured cardiomyocytes.
On the other hand, discovery of novel urinary classifiers spe-
cific for monitoring the hemodynamic status of HTx patients
can be done by support vector machine modelling and
TABLE 5.
Odds of having increased RHP
Measurement
hsTnT HF1 HF2
Odds Ratio (95% CI) P Odds Ratio (95% CI) P Odds Ratio (95% CI) P
mRAP ≥10 mm Hg
Unadjusted 1.46 (1.14 to 1.87) 0.003 1.43 (1.12 to 1.82) 0.005 1.80 (1.39 to 2.34) <0.0001
Adjusted 1.86 (1.32 to 2.62) 0.0004 1.25 (0.93 to 1.69) 0.15 1.53 (1.12 to 2.09) 0.007
Fully adjusted 2.36 (1.58 to 3.53) <0.0001 1.27 (0.92 to 1.74) 0.15 1.61 (1.15 to 2.24) 0.005
mPAP ≥24 mm Hg
Unadjusted 1.70 (1.32 to 2.20) <0.0001 1.51 (1.17 to 1.94) 0.001 1.69 (1.30 to 2.19) <0.0001
Adjusted 1.88 (1.34 to 2.62) 0.0002 1.25 (0.93 to 1.69) 0.14 1.35 (0.99 to 1.83) 0.060
Fully adjusted 1.98 (1.35 to 2.91) 0.0005 1.24 (0.90 to 1.71) 0.20 1.42 (1.01 to 1.99) 0.041
mPCWP ≥17 mm Hg
Unadjusted 1.67 (1.28 to 2.17) 0.0001 1.28 (1.00 to 1.66) 0.055 1.56 (1.20 to 2.03) 0.0009
Adjusted 2.24 (1.56 to 3.20) <0.0001 1.10 (0.81 to 1.50) 0.54 1.29 (0.94 to 1.77) 0.12
Fully adjusted 2.58 (1.70 to 3.91) <0.0001 1.09 (0.78 to 1.52) 0.61 1.34 (0.95 to 1.88) 0.094
RHPS (0, 1)
Unadjusted 1.61 (1.26 to 2.06) 0.0001 1.51 (1.19 to 1.92) 0.0007 1.76 (1.37 to 2.27) <0.0001
Adjusted 1.89 (1.38 to 2.60) <0.0001 1.31 (0.99 to 1.73) 0.063 1.50 (1.12 to 2.01) 0.007
Fully adjusted 1.99 (1.39 to 2.85) 0.0002 1.29 (0.95 to 1.73) 0.10 1.56 (1.14 to 2.12) 0.005
Estimates express the risk difference in the hemodynamic variable associated with a 1-SD increment of the biomarkers. Adjusted models account for years since transplantation, age, body mass index, mean
arterial pressure (diastolic pressure plus one third of pulse pressure on office measurement), heart rate during the right heart catheterization and serum creatinine. Fully adjusted models additionally account for use
of immunosuppressive (by class) and antihypertensive drugs. RHPS refers to having any RHP equal to or higher than the 75th percentile for mean right atrial pressure (≥10 mm Hg), mean pulmonary arterial
pressure (≥24 mm Hg) or mean pulmonary capillary wedge pressure (≥17 mm Hg).
FIGURE 3. Mean normalized values of hsTnT, HF1, and HF2 by fourths of the distributions of mRAP, mPAP, and mPCWP. P values are for
linear trend. Associations were adjusted for years since transplantation, age, body mass index, mean arterial pressure on office measurement,
heart rate during the right heart catheterization, serum creatinine, and use of immunosuppressive (by class), and antihypertensive drugs.
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methods described before for diastolic LV dysfunction4,5,19 or
chronic kidney disease.6,20
Right heart catheterization, the standard in hemodynamic
monitoring after HTx, provides mRAP, mPAP, and mPCWP,
which are indicators not only of left- and right-sided allograft
function and pulmonary vascular pressure and resistance, but
also of the systemic hemodynamic state.21,22 Mean pressures in
the right atrium and mPCWPmainly reflect right and left heart
function, while elevated LV filling pressure can be estimated by
mPCWP.23 Right heart pressures change significantly in the first
months after HTx as the allograft and the vasculature of the
host adjust to the posttransplant condition.24 Right heart cath-
eterization after this adaptive phase usually reveals smaller pres-
sure changes unless rejection occurs. In our current study, in all
the 298 HTx patients, right heart catheterization was per-
formed within 6 months of urine sampling during this stable
phase. However, a Swiss study confirmed the predictive value
of RHPs measured within 1 year (median) after HTx.22
In our current study, mRAP, mPAP, andmPCWP increased
with higher plasma troponin levels, which is consistent with
observations in patients with stable LV dysfunction or
precapillary pulmonary hypertension,25 coronary heart dis-
ease,26 heart failure,27,28 or acute rejection inHTx patients.29
Along similar lines, we previously demonstrated that plasma
hsTnT is associatedwith left atrial and LVremodeling and di-
astolic LV dysfunction.8 To our knowledge, our current study
is the first to associate RHPs with plasma levels of hsTnT in
post HTx patients. However, the most salient finding of our
current analysis is the association of mRAP and mPAP with
the urinary classifier HF2. This association is physiologically
plausible, because fibrosis is a hallmark of graft malfunction.
Under physiological conditions, the urinary proteome origi-
nates for about 70% from the kidney and the urinary tract,
while 30% is derived from plasma.30 Approximately 60% of
the total mass of urinary peptides and proteins consist of colla-
gen fragments.15 Of the urinary peptides with known amino-
acid sequence that are included in HF2, 68.9% are collagen
fragments.6 The cardiac extracellular matrix predominantly
consist of fibrillar collagen type I (85%) and type III (11%).
Although our current study cannot prove the cardiac origin
of the urinary HF2 collagen fragments, we demonstrated that
in the context of diastolic LV dysfunction circulating and uri-
nary biomarkers of fibrosis are correlated.19 Furthermore, pre-
liminary findings from tissue proteomic studies conducted
within uPROPHET3 demonstrated upregulation of proteins
involved in collagen deposition and organization of the extra-
cellular matrix in explanted diseased hearts from patients with
ischemic or DCM compared with healthy hearts offered for
implantation, but discarded because of the donors' age.31
Previous studies addressed the use of biomarkers, but
mainly in the context of acute graft rejection.32-38 The bio-
markers investigated included gene-expression profiling on
FIGURE 4. ROC curves for differentiating between RHPS 1 versus 0 for hsTnTand HF2 in all patients (n = 298) and patients with a history of
ischemic (n = 121 [ICM]) or dilated (n = 116 [DCM]) cardiomyopathy. The AUCs did not differ among the biomarkers (P ≥ 0.66) with the excep-
tion of a slight increase in the AUC for HF2 compared with hsTnT in patients with ischemic cardiomyopathy (0.56 vs 0.67; P = 0.079).
TABLE 6.
Classification parameters for higher RHPs by categories of hsTnT, HF1, and HF2
Biomarkers (threshold)
Correctly classified Incorrectly classified Classification parameters
Case Noncase Case Noncase Sensitivity (%) Specificity (%)
Positive predictive
value (%)
Negative predictive
value (%)
All patients (n = 298)
hsTnT (≥0.014 μg/L) 79 95 60 64 56.8 59.8 55.2 61.3
HF2 (≥0.15) 73 113 66 46 52.5 71.1 61.3 63.1
Ischemic cardiomyopathy (n = 121)
hsTnT (≥0.014 μg/L) 39 25 25 32 60.9 43.9 54.9 50.0
HF2 (≥0.15) 42 38 22 19 65.6 66.7 68.9 63.3
DCM (n = 116)
hsTnT (≥0.014 μg/L) 24 45 24 23 50.0 66.2 51.1 65.2
HF2 (≥0.15) 22 47 26 21 45.8 69.1 51.2 64.4
Diagnostic thresholds were≥0.014 μg/L for hsTnT (see reference17) and≥0.15 for HF2. The HF2 threshold of≥0.15 was obtained by optimizing the Youden index for identifying patients with mRAP, mPAP, or
mPCWP ≥75th percentile.
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peripheral blood32-35 or circulating microRNAs36,37 or
exosomal proteins.38 A clinical trial in the United States in-
volved 602 selected patients who had received a cardiac trans-
plant from 6 months to 5 years previously and who were at a
low risk of rejection.33 Patientswhoweremonitoredwith gene-
expression profiling and those who underwent routine biopsies
had similar 2-year cumulative rates of the composite primary
outcome (14.5% and 15.3%) and all-cause mortality (6.3%
and 5.5%). Patients who were monitored with the use of
gene-expression profiling underwent fewer biopsies per
person-year of follow-up than did patients who were mon-
itored with the use of EMB (0.5% vs 3.0%).33 This clinical
trial substantiated earlier observational studies32 and was
followed up by studies showing similar diagnostic performance
of gene-profiling compared with EMB.34,35 Other studies dem-
onstrated the potential use of microRNAs36,37 and exosomal
proteins38 as candidate biomarkers of acute rejection in the
HTx field.
To our knowledge, our current study is the first to apply
urinary proteomics for the hemodynamic assessment of
HTx patients. Its strong points are the large sample size
and the stringent quality control of the clinical, biochemical,
and proteomic variables. However, our study must also be
interpreted within the context of potential limitations. Fore-
most, the urinary biomarkers and hsTnT urine samples were
not collected within a short time interval, but only within
6 months of the right heart catheterization. The RHPs were
associated with both hsTnT and HF2, but we might have
underestimated the strength of these associations. However,
a sensitivity analysis showed comparable estimates for the
biomarkers collected within intervals of 3 months and from
3 to 6 months of the right heart catheterization. This
timeframe also precludes firm recommendation about the
time interval at which the biomarkers should be remeasured.
Such recommendation also require a research track as described
above for gene profiling.32-35 Second, the median interval
between HTx and data collection was 7.6 years (IQR,
3.2-14.3 years). We only started urine sampling from
January 2014 onward, explaining why only 39 patients
had a urine sample collected within the first year after
HTx, when acute rejection is more likely to occur. Third,
our analysis was cross-sectional. uPROPHET data collection
is currently going on to cover the first months up to 2 years
after HTx with substantially greater granularity and to en-
able a longitudinal analysis using the urinary proteomic sig-
nature as a predictor rather than as a correlate of clinical
outcomes in HTx patients. Fourth, our study is a single-
center study. That our observations are generalizable to other
HTx centers remains to be confirmed. Finally, we did not
have any measurement of N-terminal pro b-type natriuretic
peptide, because this marker was not routinely measured,
but only if severe deterioration of LV function occurred.
In conclusion, this proof-of-concept study suggests that
urinary proteomics are potentially useful in assessing the cen-
tral hemodynamics post HTx. However, further refinement
and validation of the urinary biomarkers is required before
their clinical application in this indication can be considered.
This process will involve a long path from discovery over
proving their plausibility at themolecular level to testing their
performance in randomized clinical trials compared with the
current state-of-the-art hemodynamic monitoring.
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